CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$320.26M, lower than 95% of all stocks globally
- PositionCurrent ratio is 1.23×, lower than 95% of its Biotechnology peers (median 3.43×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.52BUSDvs all stocks (USD)
Revenue (TTM)
713.07MUSDvs all stocks (USD)
Profit Margin
-97.03%vs Biotechnology peers
Beta
0.9830xvs all stocks
52-Week Change
60.05%vs all stocks
Market Capitalization
15.52BUSDvs all stocks (USD)
Enterprise Value
18.38BUSDvs all stocks (USD)
Forward P/E
518.15xvs Biotechnology peers
Price to Sales (TTM)
21.76xvs Biotechnology peers
Enterprise to Revenue
25.77xvs Biotechnology peers
Enterprise to EBITDA
-38.88xvs Biotechnology peers
Gross Margin
94.89%vs Biotechnology peers
Profit Margin
-97.03%vs Biotechnology peers
Operating Margin
-43.94%vs Biotechnology peers
Return on Assets (TTM)
-26.00%vs Biotechnology peers
Revenue (TTM)
713.07MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.67USDUpdated Aug 27, 2026Quarterly Revenue Growth
120.40%vs Biotechnology peers
Gross Profit (TTM)
673.41MUSDvs all stocks (USD)
EBITDA (TTM)
-472.75MUSDvs all stocks (USD)
Net Income (TTM)
-691.87MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
66.78%vs Biotechnology peers
Operating Cash Flow (TTM)
-434.37MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-320.26MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
10.03MUSDFY2025 · Dec 31, 2025Revenue
502.08MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
20.96MUSDFY2025 · Dec 31, 2025Gross Profit
481.11MUSDFY2025 · Dec 31, 2025Operating Income
-502.06MUSDvs all stocks (USD)
Pre-tax Income
-732.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
435.00KUSDFY2025 · Dec 31, 2025Net Income
-732.94MUSDFY2025 · Dec 31, 2025EBIT
-554.26MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-506.33MUSDFY2025 · Dec 31, 2025Research & Development
451.95MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
531.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
19.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
178.24MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.78USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.78USDFY2025 · Dec 31, 2025Basic Shares Outstanding
191.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
191.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-732.94MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
8.01MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-530.95MUSDFY2025 · Dec 31, 2025Free Cash Flow
-532.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
572.14MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.20MUSDFY2025 · Dec 31, 2025Interest Paid
43.76MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-732.94MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
5.43MUSDFY2025 · Dec 31, 2025Stock-based Compensation
133.02MUSDFY2025 · Dec 31, 2025Other Non-cash Items
136.01MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-134.72MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
26.61MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
35.64MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.10MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-8.49MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-28.20MUSDFY2025 · Dec 31, 2025Sale of Investments
11.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-18.29MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
575.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-459.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-62.50MUSDFY2025 · Dec 31, 2025Other Financing Charges
271.65MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
325.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
195.71MSharesUpdated Aug 27, 2026Float Shares
167.18MSharesUpdated Aug 27, 2026Shares Short
23.32MSharesUpdated Aug 27, 2026Short Ratio
10.88daysvs all stocks
Short % of Shares Outstanding
13.32%vs all stocks
% Held by Insiders
3.91%vs all stocks
% Held by Institutions
99.47%vs all stocks
Total Cash (MRQ)
720.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.68USDUpdated Aug 27, 2026Total Debt (MRQ)
3.37BUSDvs all stocks (USD)
Current Ratio (MRQ)
1.23xvs Biotechnology peers
Book Value per Share (MRQ)
-12.88USDUpdated Aug 27, 2026Total Assets
936.02MUSDvs all stocks (USD)
Total Current Assets
797.75MUSDFY2025 · Dec 31, 2025Total Liabilities
3.01BUSDFY2025 · Dec 31, 2025Total Non-current Assets
138.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.72BUSDFY2025 · Dec 31, 2025Total Current Liabilities
287.97MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
570.12MUSDFY2025 · Dec 31, 2025Other Short-term Investments
17.36MUSDFY2025 · Dec 31, 2025Accounts Receivable
139.44MUSDFY2025 · Dec 31, 2025Inventory
26.75MUSDFY2025 · Dec 31, 2025Accounts Payable
36.23MUSDFY2025 · Dec 31, 2025Short-term Debt
6.19MUSDFY2025 · Dec 31, 2025Deferred Revenue
18.41MUSDFY2025 · Dec 31, 2025Long-term Debt
1.86BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
244.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
202.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.82BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-2.08BUSDvs all stocks (USD)
Treasury Stock
323.28MUSDFY2025 · Dec 31, 202552-Week Low
48.78USDUpdated Aug 27, 202652-Week High
93.42USDUpdated Aug 27, 202652-Week Change
60.05%vs all stocks
Beta
0.9830xvs all stocks
50-Day MA
79.21USDUpdated Aug 27, 2026200-Day MA
73.36USDUpdated Aug 27, 2026Avg 10-Day Volume
1.97MSharesUpdated Aug 27, 2026Avg 30-Day Volume
2.07MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
-3.56USDUpdated Aug 27, 2026Other Income / Expense
-72.05MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.23×, lower than 95% of its Biotechnology peers (median 3.43×)Significant
Current ratio: 1.23Industry median: 3.43Industry P5: 1.38Peers compared: 24.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -0.97
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$320.26M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -320,264,128Global P5: -209,187,555.994
Market cap is $15.52B, above the global median of $1.18BNotable
Market cap (USD): 15,516,279,171Global Median: 1,179,398,897.704
Revenue is $713.07M, above the global median of $534.05MNotable
Revenue (USD): 713,068,992Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Ipsen S.A.
Tier 1ProductionApproval-Gated PipelineRule
Neurocrine Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jazz Pharmaceuticals plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Exelixis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Biokin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sonova Holding AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yunnan Baiyao Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Unity Software Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Via Transportation, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Twist Bioscience Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC